AlzeCure Pharma is a Swedish pharmaceutical company engaged in innovative drug research with a primary focus on Alzheimer’s disease and pain. The company is listed on Nasdaq First North Premier Growth Market and is developing five drug candidates based on the two research platforms, NeuroRestore and Alzstatin.
The NeuroRestore platform comprises symptom-relieving drug candidates while Alzstatin comprises disease modifying and preventive drug candidates. A diversified portfolio of drug candidates that act on central signaling pathways in the brain also opens up for other indications such as cognitive dysfunctions in traumatic brain injury (TBI), sleep apnea and Parkinson’s disease.
The company also has a project in the field of pain in the early preclinical phase, TrkA-NAM. FNCA Sweden AB is the company’s certified adviser: contact +46(0)8-528 00 399, info@fnca.se. For further information, please visit our website at www.alzecurepharma.se.
Company Details
- Employees
- 15
- Founded
- -
- Address
- Hälsovägen 7, Stockholm,stockholm County 14157,sweden
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.alzecurepharma.com
- HQ
- Stockholm, Stockholm County
Alzecure Pharma Questions
Alzecure Pharma's website is http://www.alzecurepharma.com
Alzecure Pharma's LinkedIn profile is https://se.linkedin.com/company/alzecure
Alzecure Pharma has
15 employees.
View email and phone details for 15
employees at Alzecure Pharma.
Alzecure Pharma's industry is
Biotechnology Research
Alzecure Pharma's top competitors are
Nextcell Pharma Ab,
Oncopeptides Ab (Publ),
Medivir Ab,
Calliditas Therapeutics,
Bioarctic,
Biolamina,
Anocca,
Sprint Bioscience,
Pelago Bioscience Ab,
Affibody Ab.
Alzecure Pharma's categories are Biotechnology Research
Alzecure Pharma's founding year is 2016
